NVO logo

Novo Nordisk A/S (NVO) Accounts receivable

Annual accounts receivable:

$9.99B+$392.79M(+4.09%)
December 31, 2024

Summary

  • As of today (September 9, 2025), NVO annual accounts receivable is $9.99 billion, with the most recent change of +$392.79 million (+4.09%) on December 31, 2024.
  • During the last 3 years, NVO annual accounts receivable has risen by +$3.78 billion (+60.77%).
  • NVO annual accounts receivable is now at all-time high.

Performance

NVO Accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNVObalance sheet metrics

Quarterly accounts receivable:

$10.95B+$889.94M(+8.85%)
June 1, 2025

Summary

  • As of today (September 9, 2025), NVO quarterly accounts receivable is $10.95 billion, with the most recent change of +$889.94 million (+8.85%) on June 1, 2025.
  • Over the past year, NVO quarterly accounts receivable has increased by +$1.81 billion (+19.83%).
  • NVO quarterly accounts receivable is now at all-time high.

Performance

NVO Quarterly accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNVObalance sheet metrics

Accounts receivable Formula

Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales

NVO Accounts receivable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+4.1%+19.8%
3 y3 years+60.8%+90.7%
5 y5 years+167.0%+182.8%

NVO Accounts receivable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+60.8%at high+90.7%
5 y5-yearat high+167.0%at high+185.3%
alltimeall timeat high+4800.6%at high+2282.9%

NVO Accounts receivable History

DateAnnualQuarterly
Jun 2025
-
$10.95B(+8.8%)
Mar 2025
-
$10.06B(+0.7%)
Dec 2024
$9.99B(+4.1%)
$9.99B(+0.7%)
Sep 2024
-
$9.93B(+8.7%)
Jun 2024
-
$9.14B(+10.7%)
Mar 2024
-
$8.25B(-14.0%)
Dec 2023
$9.60B(+32.3%)
$9.60B(+28.5%)
Sep 2023
-
$7.47B(-16.8%)
Jun 2023
-
$8.98B(+21.9%)
Mar 2023
-
$7.37B(+1.5%)
Dec 2022
$7.26B(+16.8%)
$7.26B(+20.9%)
Sep 2022
-
$6.00B(+4.6%)
Jun 2022
-
$5.74B(+5.9%)
Mar 2022
-
$5.42B(-12.8%)
Dec 2021
$6.21B(+36.3%)
$6.21B(+33.5%)
Sep 2021
-
$4.65B(+11.8%)
Jun 2021
-
$4.16B(-6.0%)
Mar 2021
-
$4.43B(-2.8%)
Dec 2020
$4.56B(+21.8%)
$4.56B(+18.8%)
Sep 2020
-
$3.84B(-0.9%)
Jun 2020
-
$3.87B(-12.5%)
Mar 2020
-
$4.42B(+18.2%)
Dec 2019
$3.74B(+7.2%)
$3.74B(+13.8%)
Sep 2019
-
$3.29B(-7.3%)
Jun 2019
-
$3.55B(+9.8%)
Mar 2019
-
$3.23B(-7.4%)
Dec 2018
$3.49B(+7.3%)
$3.49B(+20.9%)
Sep 2018
-
$2.89B(-2.9%)
Jun 2018
-
$2.97B(+10.3%)
Mar 2018
-
$2.70B(-17.1%)
Dec 2017
$3.25B(+13.3%)
$3.25B(+19.0%)
Sep 2017
-
$2.73B(+2.6%)
Jun 2017
-
$2.66B(+8.9%)
Mar 2017
-
$2.45B(-14.8%)
Dec 2016
$2.87B(+27.3%)
$2.87B(+17.2%)
Sep 2016
-
$2.45B(+4.1%)
Jun 2016
-
$2.35B(-6.8%)
Mar 2016
-
$2.52B(+12.0%)
Dec 2015
$2.25B(+6.4%)
$2.25B(+11.1%)
Sep 2015
-
$2.03B(-4.4%)
Jun 2015
-
$2.12B(+0.8%)
Mar 2015
-
$2.11B(-0.6%)
DateAnnualQuarterly
Dec 2014
$2.12B(+5.2%)
$2.12B(+15.5%)
Sep 2014
-
$1.83B(-13.2%)
Jun 2014
-
$2.11B(+9.3%)
Mar 2014
-
$1.93B(-4.0%)
Dec 2013
$2.01B(+18.3%)
$2.01B(+14.2%)
Sep 2013
-
$1.76B(-7.9%)
Jun 2013
-
$1.92B(+5.1%)
Mar 2013
-
$1.82B(+7.0%)
Dec 2012
$1.70B(+4.3%)
$1.70B(+1.8%)
Sep 2012
-
$1.67B(-1.3%)
Jun 2012
-
$1.69B(-1.2%)
Mar 2012
-
$1.71B(+5.0%)
Dec 2011
$1.63B(+6.7%)
$1.63B(+0.0%)
Sep 2011
-
$1.63B(-11.0%)
Jun 2011
-
$1.83B(+5.6%)
Mar 2011
-
$1.74B(+13.5%)
Dec 2010
$1.53B(+12.4%)
$1.53B(-1.9%)
Sep 2010
-
$1.56B(+9.5%)
Jun 2010
-
$1.42B(-3.8%)
Mar 2010
-
$1.48B(+24.4%)
Dec 2009
$1.36B(+10.8%)
-
Mar 2009
-
$1.19B(-9.5%)
Dec 2008
$1.23B(+2.9%)
-
Mar 2008
-
$1.32B(+144.3%)
Dec 2007
$1.19B(+30.8%)
-
Dec 2006
$913.30M(+20.5%)
-
Dec 2005
$758.13M(+2.1%)
-
Dec 2004
$742.25M(+15.1%)
-
Dec 2003
$645.08M(+19.8%)
-
Dec 2002
$538.40M(+15.8%)
$538.40M(+17.2%)
Dec 2001
$464.89M(+8.8%)
$459.38M(-21.7%)
Dec 2000
$427.18M(-13.2%)
$587.05M(-20.7%)
Dec 1999
$492.30M(-7.9%)
$740.38M(-17.2%)
Dec 1998
$534.37M(+3.2%)
$893.87M
Dec 1997
$517.86M(-11.6%)
-
Dec 1996
$585.53M(+16.2%)
-
Dec 1995
$503.79M(+11.6%)
-
Dec 1994
$451.57M(+15.5%)
-
Dec 1993
$391.12M(+12.9%)
-
Dec 1992
$346.39M(+9.3%)
-
Dec 1991
$316.86M(+3.3%)
-
Dec 1990
$306.81M(+50.5%)
-
Dec 1989
$203.87M
-

FAQ

  • What is Novo Nordisk A/S annual accounts receivable?
  • What is the all time high annual accounts receivable for Novo Nordisk A/S?
  • What is Novo Nordisk A/S annual accounts receivable year-on-year change?
  • What is Novo Nordisk A/S quarterly accounts receivable?
  • What is the all time high quarterly accounts receivable for Novo Nordisk A/S?
  • What is Novo Nordisk A/S quarterly accounts receivable year-on-year change?

What is Novo Nordisk A/S annual accounts receivable?

The current annual accounts receivable of NVO is $9.99B

What is the all time high annual accounts receivable for Novo Nordisk A/S?

Novo Nordisk A/S all-time high annual accounts receivable is $9.99B

What is Novo Nordisk A/S annual accounts receivable year-on-year change?

Over the past year, NVO annual accounts receivable has changed by +$392.79M (+4.09%)

What is Novo Nordisk A/S quarterly accounts receivable?

The current quarterly accounts receivable of NVO is $10.95B

What is the all time high quarterly accounts receivable for Novo Nordisk A/S?

Novo Nordisk A/S all-time high quarterly accounts receivable is $10.95B

What is Novo Nordisk A/S quarterly accounts receivable year-on-year change?

Over the past year, NVO quarterly accounts receivable has changed by +$1.81B (+19.83%)
On this page